Development of a multivalent Shigella bioconjugate vaccine

A genetically engineered *E. coli* bacterium is being turned into a living factory to produce a vaccine that could prevent deadly dysentery in children. This matters because shigellosis—a severe diarrhoeal disease caused by *Shigella* bacteria—kills hundreds of thousands of young children in developing countries each year, and no broadly effective vaccine currently exists. The core challenge is that the bacterium’s protective surface sugars must be chemically linked to a protein to trigger a strong immune response, but traditional chemical conjugation is complex and expensive. The GlycoVaxyn technology sidesteps this by engineering *E. coli* to assemble the sugar–protein complex directly inside its own cells, producing a “bioconjugate” vaccine in a single biological step. If this approach succeeds, it could transform vaccine manufacturing for low-resource settings. A multivalent shot—protecting against multiple *Shigella* strains at once—would be cheaper and faster to produce than existing chemical conjugates, and could be scaled up to reach the children who need it most. The same bioconjugation platform might also be adapted to tackle other bacterial diseases that currently lack effective vaccines.